Physician profile
Stuart Hensley
NPI 1205617305
$3,007.47
in general payments reported to CMS, 2019-2025
23 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,836 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $950.66 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $271.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $235.59 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $202.23 | 2024 | Epclusa |
| Amgen INC. | $185.27 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $157.67 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $123.66 | 2024-2025 | Trelegy Ellipta, Penmenvy, Arexvy |
| Idorsia Pharmaceuticals US INC | $120.84 | 2024 | Quviviq |
| Lundbeck LLC | $94.32 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.88 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $86.59 | 2024-2025 | Zerbaxa, Dificid, Pifeltro |
| Paratek Pharmaceuticals, INC. | $70.49 | 2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $65.33 | 2025 | Vowst |
| Abbvie INC. | $63.69 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $55.02 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $54.27 | 2024 | Arikayce |
| Verona Pharma, INC. | $39.68 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $29.95 | 2024 | |
| Qol Medical, LLC | $27.00 | 2024 | Sucraid |
| Otsuka America Pharmaceutical, INC. | $26.97 | 2024 | Rexulti |
| Viiv Healthcare Company | $21.01 | 2025 | Apretude |
| E.R. Squibb & Sons, L.L.C. | $20.39 | 2024 | Eliquis |
| Phadia US INC. | $15.99 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.